Form 4: Niagen CFO Ozan Granted 62,131 Stock Options

Niagen Bioscience's Chief Financial Officer, Ozan Pamir, was granted 62,131 employee stock options with an exercise price of $4.94, vesting over four years.

Summary

• Niagen Bioscience, Inc. (NAGE) Chief Financial Officer, Ozan Pamir, was granted 62,131 employee stock options.
• The options have an exercise price of $4.94 per share.
• The grant date for these options was February 19, 2026.
• The options will vest over four years, with one-fourth vesting on each anniversary of the grant date.
• The first tranche of options will become exercisable on February 19, 2027.
• The options have an expiration date of February 18, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it aligns executive incentives with shareholder interests, a standard corporate governance practice, without indicating any immediate operational or financial changes.

Positives

• The grant of stock options aligns the Chief Financial Officer's interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages retention of key management personnel over a four-year period.

Negatives

• The exercise of these options in the future could lead to a slight dilution of existing shareholders' equity, although this is a standard practice for employee compensation.

Risks

• The value of the options is dependent on the future market price of Niagen Bioscience, Inc. common stock exceeding the exercise price of $4.94.
• If the company's stock price does not increase above the exercise price, the options may not be "in the money" and could expire worthless.
• The vesting schedule means the full benefit of the options is not immediate and is contingent on continued employment.

Future Outlook

The options are structured to vest over four years, indicating a long-term incentive for the CFO, with the first tranche becoming exercisable on February 19, 2027.

Industry Context

StockSavvy.ai notes that granting stock options to key executives like the CFO is a common practice across industries, particularly in biotechnology and growth-oriented companies, to attract, retain, and motivate talent by aligning their financial incentives with shareholder value creation.

Comparison to Industry Standards

• The grant of 62,131 options to a CFO is within the typical range for executive compensation packages in small to mid-cap biotechnology firms, comparable to grants seen at companies like BioXcel Therapeutics or Atea Pharmaceuticals for similar roles, depending on company size and performance.
• An exercise price of $4.94, likely at or above the market price on the grant date, is standard for incentive stock options, ensuring the executive benefits only if the stock price appreciates.
• A four-year vesting schedule with annual tranches is a widely adopted industry standard for executive equity compensation, promoting long-term commitment and performance.

Stakeholder Impact

• Shareholders: Potential for long-term value creation if the CFO's incentives lead to improved company performance; minor potential for dilution upon option exercise.
• Employees: May signal stability in executive leadership and a commitment to performance-based compensation.
• Management: Provides a significant long-term incentive and compensation component for the Chief Financial Officer.

Next Steps

• The options will vest annually, with the first vesting event on February 19, 2027.
• The Chief Financial Officer may choose to exercise vested options at any point before the expiration date of February 18, 2036, assuming the stock price is favorable.

Key Dates

Recommendation

This Form 4 filing is a routine disclosure of executive compensation and does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It primarily indicates standard corporate governance practices and executive incentive alignment.

Keywords

Niagen Bioscience, NAGE, Stock Options, CFO, Executive Compensation, Form 4, Insider Transaction, Equity Grant, Vesting